NRC Form 4: Director Berwick awarded 22,625 options at $11.61
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
National Research Corp (NRC): Director stock option grant reported. A Form 4 shows Donald M. Berwick, a director, was granted 22,625 stock options on 10/17/2025 under the Issuer's 2025 Omnibus Incentive Plan for participating in two in-person meetings during 2025.
The options have an exercise price of $11.61 per share, became exercisable on 10/17/2025, and expire on 10/17/2035. The derivative acquisition price was listed as $0. Ownership is reported as Direct (D).
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Berwick Donald M
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 22,625 | $0.00 | -- |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 22,625 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did NRC (NRC) disclose in this Form 4?
A director, Donald M. Berwick, received a grant of 22,625 stock options on 10/17/2025.
How many options were granted and at what exercise price for NRC (NRC)?
The grant was for 22,625 options with an exercise price of $11.61 per share.
When do the granted NRC (NRC) options become exercisable and when do they expire?
They became exercisable on 10/17/2025 and expire on 10/17/2035.
What plan governed the NRC (NRC) director’s option grant?
The grant was made under the Issuer’s 2025 Omnibus Incentive Plan.
Why was the option grant made to the NRC (NRC) director?
It was for participating in two in-person meetings during 2025, per the explanation of responses.
What was the derivative security price listed in the NRC (NRC) Form 4?
The Form 4 lists a derivative security price of $0.
How is ownership reported for this NRC (NRC) option grant?
Ownership is reported as Direct (D).